Hypoparathyroidism secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 12: | Line 12: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
* | *Effective measures for the secondary prevention of hypoparathyroidism is monitoring patients on conventional tharapy. Monitoring guidelines on conventional therapy include:<ref name="pmid26943719">{{cite journal |vauthors=Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT |title=Management of Hypoparathyroidism: Summary Statement and Guidelines |journal=J. Clin. Endocrinol. Metab. |volume=101 |issue=6 |pages=2273–83 |year=2016 |pmid=26943719 |doi=10.1210/jc.2015-3907 |url=}}</ref><ref name="pmid26938200">{{cite journal |vauthors=Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT |title=Management of Hypoparathyroidism: Present and Future |journal=J. Clin. Endocrinol. Metab. |volume=101 |issue=6 |pages=2313–24 |year=2016 |pmid=26938200 |pmc=5393596 |doi=10.1210/jc.2015-3910 |url=}}</ref> | ||
**Serum calcium (corrected for albumin), phosphorus, and creatinine concentrations should be measured weekly to monthly during dose adjustments, and twice annually once a stable regimen has been reached. | |||
* | **24 hour Urinary calcium and urine creatinine should be considered during dose adjustments and should be measured twice annually on a stable regimen to evaluate for renal toxicity. | ||
** | **Estimated gomerular filtration rate (eGFR) should be monitored yearly or more frequently if the clinical situation is appropriate. | ||
** | *Other imaging studies and examinations may be done as clinically indicated. | ||
** | **Renal imaging may be done to rule out nephrolithiasis/nephrocalcinosis. | ||
**Ophthalmological exam may be done to rule out cataracts. | |||
**Central nervous system imaging may be done to rule out basal ganglia and other sites of calcification. | |||
**Bone mineral density may be done to rule out to rule out skeletal abnormalities. | |||
==References== | ==References== | ||
Revision as of 18:37, 22 September 2017
|
Hypoparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypoparathyroidism secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hypoparathyroidism secondary prevention |
|
Risk calculators and risk factors for Hypoparathyroidism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
- Effective measures for the secondary prevention of hypoparathyroidism is monitoring patients on conventional tharapy. Monitoring guidelines on conventional therapy include:[1][2]
- Serum calcium (corrected for albumin), phosphorus, and creatinine concentrations should be measured weekly to monthly during dose adjustments, and twice annually once a stable regimen has been reached.
- 24 hour Urinary calcium and urine creatinine should be considered during dose adjustments and should be measured twice annually on a stable regimen to evaluate for renal toxicity.
- Estimated gomerular filtration rate (eGFR) should be monitored yearly or more frequently if the clinical situation is appropriate.
- Other imaging studies and examinations may be done as clinically indicated.
- Renal imaging may be done to rule out nephrolithiasis/nephrocalcinosis.
- Ophthalmological exam may be done to rule out cataracts.
- Central nervous system imaging may be done to rule out basal ganglia and other sites of calcification.
- Bone mineral density may be done to rule out to rule out skeletal abnormalities.
References
- ↑ Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT (2016). "Management of Hypoparathyroidism: Summary Statement and Guidelines". J. Clin. Endocrinol. Metab. 101 (6): 2273–83. doi:10.1210/jc.2015-3907. PMID 26943719.
- ↑ Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT (2016). "Management of Hypoparathyroidism: Present and Future". J. Clin. Endocrinol. Metab. 101 (6): 2313–24. doi:10.1210/jc.2015-3910. PMC 5393596. PMID 26938200.